Synthesis and evaluation of a pyrazinoic acid prodrug in Mycobacterium tuberculosis

Saudi Pharm J. 2014 Sep;22(4):376-80. doi: 10.1016/j.jsps.2013.12.005. Epub 2013 Dec 25.

Abstract

Tuberculosis (TB) is a disease caused mainly by infection of Mycobacterium tuberculosis affecting more than ten million people around the world. Despite TB can be treated, the rise of MDR-TB and XDR-TB cases put the disease in a worrying status. As pyrazinamide-resistant strains exhibit low or none pyrazinamidase activity, it is proposed that the active form of pyrazinamide (PZA) is pyrazinoic acid (POA), although this acid has poor penetration in mycobacteria. In this work, we present a convenient one-pot synthesis of 2-chloroethyl pyrazinoate, and its activity in M. tuberculosis H37Rv (ATCC27294) in MIC assay using the MABA technique. The obtained MIC of the compound was 3.96 g/mL, and discussion about the activity profile of some previously evaluated pyrazinoates is also performed.

Keywords: Antimycobacterial agent; Ester synthesis; Prodrug; Pyrazinoic acid; Tuberculostatic.